Treatment of Recurrent Erythema Multiforme — HSV-Associated or Idiopathic
Erythema multiforme can follow a recurrent pattern in some patients, arising either in the setting of herpes simplex virus (HSV) infection or without an identifiable trigger. Managing repeated episodes requires a structured approach that accounts for the underlying cause and the adequacy of initial preventive therapy.
This protocol addresses recurrent erythema multiforme, covering both HSV-associated and idiopathic presentations. In both forms, antiviral prophylaxis represents the established first-line strategy. Where recurrence continues despite this approach, additional systemic treatment options are indicated.
Treatment Approach
For recurrent EM that proves resistant to prophylactic antiviral therapy, the protocol outlines a range of specific systemic agents spanning multiple therapeutic classes — the complete evidence-based regimen, including sequencing and agent selection, is available in the full protocol.
References
DOI: 10.3390/medicina57090921
- In both HSV-associated EM and idiopathic EM, the first-line treatment is antiviral prophylaxis.
- Additionally, other systemic agents may be used.
- If resistant to prophylactic antivirals, systemic agents that may be used include: azathioprine, dapsone, mycophenolate mofetil, or immunoglobulin hydroxychloroquine, thalidomide, and cyclosporine.
- Antibiotics, azithromycin, and dapsone specifically, have both produced clinical improvement in patients with recurrent EM.
- An observational study from 2018 demonstrated that levamisole showed significant reduction in EM recurrence in 23 patients, compared to standard therapy with corticosteroids and antiviral therapy.
- Additionally, a single patient with recurrent EM had a rapid and complete response to treatment with adalimumab.
- Another case series from 2017 described the use of apremilast in 3 patients with recurrent oral EM.
View source ↗